Joint Clinical Trials Office
A Phase 1b/2 Study of BGB-11417 as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Study Status:
Open to Enrollment
Primary Investigator:
Date: November 26, 2024
A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participants with Prostate Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: November 26, 2024
A Phase 1, Multicenter, Open-Label Study of CB-012, a CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Study Status:
Open to Enrollment
Primary Investigator:
Date: November 26, 2024
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC)
Study Status:
Open to Enrollment
Primary Investigator:
Date: November 1, 2024
A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment For Relapsed/Refractory Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 29, 2024
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25 (OFSET)
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 10, 2024
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 2, 2024
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 2, 2024
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next-Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 2, 2024
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 2, 2024